C12N 2501/72
Transferases [ec 2.]
Official title: Transferases [EC 2.]
C12N2501/72 (Transferases [ec 2.]) appears on 790 US grants and 2,092 published applications in this corpus.
Search patents in C12N- Granted patents
- 790
- Published applications
- 2,092
- Assignees
- 791
- Inventors
- 3,718
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 3 |
| 2007 | 0 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 4 |
| 2010 | 0 | 12 |
| 2011 | 1 | 19 |
| 2012 | 2 | 29 |
| 2013 | 5 | 44 |
| 2014 | 9 | 45 |
| 2015 | 28 | 66 |
| 2016 | 34 | 115 |
| 2017 | 40 | 127 |
| 2018 | 61 | 130 |
| 2019 | 87 | 147 |
| 2020 | 73 | 141 |
| 2021 | 72 | 189 |
| 2022 | 69 | 181 |
| 2023 | 72 | 191 |
| 2024 | 87 | 244 |
| 2025 | 88 | 225 |
| 2026 | 62 | 174 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Composition for enhancing reprogramming efficiency from somatic cell to induced pluripotent stem cell, comprising mTOR activator, and method for enhancing reprogramming efficiency by using same6 Oct 2026US 12,753,394 B2Korea University Research and Business Foundation
- Ex vivo proliferation of epithelial cells29 Sep 2026US 12,747,425 B2Propagenix Inc.
- Generation of uniform hepatocytes from human embryonic stem cells by inhibiting TGF-beta and methods of maintaining hepatic cultures15 Sep 2026US 12,734,197 B2Wisconsin Alumni Research Foundation
- Maintenance and/or culture of tissue slices in vitro or ex vivo15 Sep 2026US 12,736,523 B2National University of Singapore
- Methods and compositions for generating oligodendrocyte progenitor cells8 Sep 2026US 12,729,368 B2Trailhead Biosystems Inc.
- Method for producing high-titer viral vector8 Oct 2026US 2026/0308534 A1Kaneka Corporation
- Cryopreserved endocrine cells that express chromogranin a1 Oct 2026US 2026/0294981 A1ViaCyte, Inc.
- Method for modulating the differentiation and functions of human dendritic cells1 Oct 2026US 2026/0297524 A1Centre National De La Recherche Scientifique
- Oct3/4 protein variants, and method for producing induced pluripotent stem cells1 Oct 2026US 2026/0297535 A1Riken
- Reprogramming methods and cell culture platforms1 Oct 2026US 2026/0297537 A1Fate Therapeutics, Inc.
Most cited
By later US patents
- In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells86US 8,859,286 B2ViaCyte, Inc. · 2014
- Cell compositions derived from dedifferentiated reprogrammed cells51US 9,109,245 B2ViaCyte, Inc. · 2015
- SC-β cells and compositions and methods for generating the same50US 10,030,229 B2President and Fellows of Harvard College · 2018
- Selective oxidation of 5-methylcytosine by TET-family proteins46US 9,447,452 B2Children's Medical Center Corporation · 2016
- Selective oxidation of 5-methylcytosine by TET-family proteins41US 9,115,386 B2Children's Medical Center Corporation · 2015